Hadassah considers Argentina for phase III vaccine trial against Israeli COVID-19 – fr

0
24
Hadassah considers Argentina for phase III vaccine trial against Israeli COVID-19 – fr


A team of health professionals from Hadassah University Medical Center left for coronavirus-stricken Argentina on Friday morning to discuss the possibility of conducting a phase III clinical study of Israel’s COVID-19 vaccine. Israel will also explore the possibility of manufacturing the vaccine, if successful, in Argentina. Israel’s vaccine candidate, BriLife, is currently in the middle of its Phase II trial. Since the majority of Israelis are vaccinated, the country will need to conduct a larger Phase III trial with around 30,000 people overseas. Other countries considered for the trial are Spain, England, United Arab Emirates, India, Mexico, Brazil and even the United States, said Professor Dror Mevorach, who will join the mission on Sunday. He said Le Jerusalem Post that Argentina has requested to be considered for the trial and is therefore the last candidate. Negotiations with other countries are more advanced, he said, adding that the remoteness of the country from Israel could pose logistical problems. It takes about 24 hours to get to Argentina from Israel. In March, Professor Yossi Caraco of Hadassah, director of Hadassah’s clinical research unit, said the hospital had signed a memorandum of understanding with Brazil to conduct the phase III trial. However, Mevorach said little progress has been made since then.
Caraco is on a mission.

The hope is to complete the much delayed Phase II clinical trial in the weeks or months to come, and then move on to the next step.

The delegation, led by Professor Yoram Weiss, director of Hadassah Ein Kerem Hospital, will meet with senior government officials and provide medical knowledge and support to the ailing country. “We’re coming to share our knowledge and see what we can bring out of our experience, and maybe we’ll learn things that they know,” Weiss told the Poster.

The week-long mission began the same day the Health Ministry announced its intention to ask the government to add Argentina to the list of “dangerous countries” from which returnees must enter quarantine, which ‘they are vaccinated or not.

If the country is added, it will join a list of seven other countries including Ukraine, Ethiopia, Brazil, India, South Africa, Mexico and Turkey in which Israelis are not allowed to travel without special authorization.

The Hadassah mission to Argentina was requested and is funded by the Argentine government and was organized by Hadassah International. Professor Sigal Sviri, director of the medical intensive care department, who also headed the COVID-19 intensive care unit at Hadassah, is on a mission, and the team and other medical staff are expected to meet with President Alberto Fernández , Minister of Foreign Affairs Felipe Sola and Minister of Health Carla Vizzotti.

The delegation will help the country initiate the use of a ‘passive vaccine’ or antibody treatment developed by Hadassah with the Israeli biopharmaceutical company Kamada which uses the plasma that Hadassah has collected from recovered corona patients – those who had the disease and who are now testing negative for the virus. Hadassah used the treatment at the height of the crisis in Israel and reported rapid clinical benefits. He will also share his experiences fighting COVID-19 in Israel, Mevorach said. “I think we will study the specific situation in Argentina and try to see if there is anything that can be shared that we have learned during the pandemic,” Mevorach told the PosterHe noted that he was “concerned” about the high level of infection in the country, despite having been vaccinated. The Brazilian variant, which some say may be at least partially resistant to vaccines, is dominant in Argentina.

The health ministry also warned citizens against travel to Seychelles, Georgia, Moldova, Maldives, Philippines, France, Costa Rica, Cyprus, Russia and Thailand on Friday – all countries at high level of infection – although no formal restrictions have been implemented.

LEAVE A REPLY

Please enter your comment!
Please enter your name here